

08 March 2024

Biological Treatments for Melanoma And Renal Cell Carcinoma

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- Avelumab + Axitinib <5
- Axinitib <5
- Cabozantinib 15
- Everolimus <5
- Lenvatinib + Everolimus <5
- Nivolumab monotherapy 15
- Nivolumab + Cabozantinib 16
- Nivolumab + Ipilimumab <5
- Pazopanib <5
- Pembrolizumab monotherapy 37
- Pembrolizumab + Lenvatinib 6
- Pembrolizumab + Axitinib <5
- Radiotherapy only not available on RISOH
- Sunitinib <5
- Temsirolimus <5
- Tivozanib 11
- Other active systemic anti-cancer therapy <5
- Palliative care only not specified on RISOH

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :

- Cobimetinib <5
- Dabrafenib <5
- Dabrafenib + Trametinib 16
- Dacarbazine <5
- Denosumab tumour site not specified on RISOH
- Encorafenib + Binimetinib 26
- Ipilimumab monotherapy <5
- Ipilimumab + Nivolumab 10
- Nivolumab monotherapy 10
- Nivolumab + Relatlimab <5
- Pembrolizumab 56

08 March 2024

- Trametinib <5
- Vemurafenib <5
- Vemurafenib + Cobimetinib <5
- Other active systemic anti-cancer therapy Tebentafusp MAP <5
- Palliative care only not specified on RISOH

Q3. Does you trust participate in any clinical trials for the treatment of melanoma? If so please provide the name of each trial and number of patients that are taking part?

Renal Cancer Trial/Study Activity 1 March 2024			
CLIN 60000	A prospective observational international study of cabozantinib tablets in combination with nivolumab as first-line treatment of advanced renal cell carcinoma in adults	6	Open

Skin Cancer (Melanoma) Trial/Study Activity 1 March 2024			
No active trials			

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.